X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (248) 248
Newspaper Article (37) 37
Publication (15) 15
Magazine Article (8) 8
Book / eBook (2) 2
Book Review (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117) 117
female (111) 111
oncology (108) 108
middle aged (96) 96
index medicus (93) 93
aged (88) 88
adult (83) 83
breast cancer (72) 72
breast neoplasms - drug therapy (72) 72
breast neoplasms - pathology (58) 58
chemotherapy (54) 54
treatment outcome (54) 54
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
aged, 80 and over (45) 45
disease-free survival (42) 42
antineoplastic combined chemotherapy protocols - adverse effects (40) 40
paclitaxel (36) 36
metastasis (32) 32
trastuzumab (32) 32
breast neoplasms - mortality (30) 30
cancer (30) 30
care and treatment (30) 30
neoplasm staging (29) 29
hematology, oncology and palliative medicine (28) 28
neoplasm metastasis (28) 28
male (27) 27
survival (27) 27
therapy (26) 26
medicine & public health (25) 25
deoxycytidine - analogs & derivatives (24) 24
bevacizumab (23) 23
breast neoplasms - metabolism (23) 23
metastatic breast cancer (23) 23
receptor, erbb-2 - metabolism (23) 23
antineoplastic agents - therapeutic use (22) 22
deoxycytidine - administration & dosage (22) 22
docetaxel (21) 21
drug administration schedule (21) 21
paclitaxel - administration & dosage (21) 21
obstetrics and gynecology (20) 20
trial (20) 20
antineoplastic combined chemotherapy protocols - administration & dosage (19) 19
combination (19) 19
kaplan-meier estimate (18) 18
research (18) 18
capecitabine (17) 17
clinical trials (17) 17
women (17) 17
carboplatin - administration & dosage (15) 15
efficacy (15) 15
her2 (15) 15
patient outcomes (15) 15
young adult (15) 15
antibodies, monoclonal - administration & dosage (14) 14
antibodies, monoclonal, humanized (14) 14
drug therapy (14) 14
anthracycline (13) 13
carcinoma (13) 13
prognosis (13) 13
survival analysis (13) 13
survival rate (13) 13
antineoplastic agents - administration & dosage (12) 12
antineoplastic agents - adverse effects (12) 12
double-blind (12) 12
doxorubicin (12) 12
metastases (12) 12
patients (12) 12
receptor, erbb-2 - genetics (12) 12
adjuvant chemotherapy (11) 11
antibodies, monoclonal - adverse effects (11) 11
antibodies, monoclonal, humanized - administration & dosage (11) 11
cancer therapies (11) 11
deoxycytidine - adverse effects (11) 11
oncology, experimental (11) 11
tumors (11) 11
analysis (10) 10
antibodies, monoclonal - therapeutic use (10) 10
breast neoplasms - genetics (10) 10
cancer patients (10) 10
paclitaxel - adverse effects (10) 10
safety (10) 10
taxoids - administration & dosage (10) 10
article (9) 9
biomarkers, tumor - metabolism (9) 9
cancer research (9) 9
carboplatin (9) 9
cisplatin (9) 9
disease progression (9) 9
double-blind method (9) 9
lung neoplasms - drug therapy (9) 9
monoclonal-antibody (9) 9
multicenter (9) 9
plus (9) 9
receptor, erbb-2 - antagonists & inhibitors (9) 9
skin and connective tissue diseases (9) 9
taxane (9) 9
time factors (9) 9
antibodies, monoclonal, humanized - adverse effects (8) 8
antibodies, monoclonal, humanized - therapeutic use (8) 8
antimitotic agents (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 34_suppl, pp. 141 - 141
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13057 - e13057
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2009, Volume 15, Issue 4, pp. 1452 - 1459
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 31_suppl, pp. 239 - 239
Journal Article
American Journal of Cancer, ISSN 1175-6357, 2005, Volume 4, Issue 5, pp. 334 - 335
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 08/2019, Volume 15, Issue 23, pp. 2673 - 2686
Ribociclib has received approval in the pre/peri- and postmenopausal disease settings on the basis of the MONALEESA trials. MONALEESA-2 demonstrated that... 
breast cancer | MONALEESA-7 | COMBINATION | MONALEESA-2 | CDK4/6 inhibitor | MONALEESA-3 | BREAST-CANCER | PALBOCICLIB | WOMEN | THERAPY | ONCOLOGY | FULVESTRANT | premenopausal | ABEMACICLIB | ribociclib | postmenopausal | PLUS
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 811 - 821
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2014, Volume 14, Issue 5, pp. 297 - 308
Breast cancer (BC) is diagnosed in nearly 1 in 3 women with cancer in the United States; one third of these patients have regional lymph node metastases at the... 
Infection | Noninfectious pneumonitis | Rash | Stomatitis | Advanced breast cancer | Adverse events | mTOR | Everolimus
Journal Article
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 18, pp. 1738 - 1748
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article